Guardant Health Inc GH

NAS: GH | ISIN: US40131M1099 26/04/2024

17,35 USD (+1,11%)

(+1,11%) 26/04/2024

Grafiek Guardant Health Inc

Grafiek Guardant Health Inc

1 dag1d 1,11%
1 week1w 7,97%
1 maand1m -1,92%
3 maanden3m -24,89%
6 maanden6m -32,15%
1 jaar1j -17,14%
5 jaar5j -74,26%

donderdag 9 mei 2024, 22:00

Kwartaalcijfers (1ste kwartaal)

Guardant Health Inc in het nieuws

Toon enkel gratis nieuws

8 januari 2024 · Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa · Persbericht

13 november 2023 · Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea · Persbericht

30 mei 2023 · Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers · Persbericht

6 juli 2022 · Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China · Persbericht

20 juli 2021 · AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round · Persbericht

Profiel Guardant Health Inc

Gezondheidszorg

Medische/verpleegkundige diensten

Tandheelkundige laboratoria

CEO: Helmy Eltoukhy

Werknemers: 2.284

Aandelen Guardant Health Inc

Beurswaarde: 2,09 miljard USD

Effecten: 121,71 miljoen

Winst per aandeel (12 maand): PLUS

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe